Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Terry Chrisomalis
Investing Group Leader
(15min)

Summary

  • FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences.
  • Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders.
  • Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well.
  • Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Hands of Chemist in Gloves Dripping Liquid into Petri Dish Studying Bacteria at Table in Lab

SeventyFour

Nurix Therapeutics, Inc. (NASDAQ:NRIX) just announced today that it had received IND clearance from the FDA for its BTK degrader GS-6791, which is being developed to target inflammatory disorders. In essence, going after such disorders like rheumatoid arthritis (RA) and

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About NRIX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NRIX

Related Stocks

SymbolLast Price% Chg
NRIX
--
Compare

Trending Analysis

Trending News

OSZAR »